Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting

Amsterdam, The Netherlands, October 26, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that a poster was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually from November 9-14, 2020.

The details of the poster presentation are as follows:

• Poster #454: Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures
  Presenter: Namita Varudkar
  Affiliation: University of Central Florida
  Session category: Combination immunotherapies
  Presentation Dates: Thursday, November 12, 4:50-5:20 p.m. EST and Saturday, November 14, 1:00-1:30 p.m. EST

All abstracts are scheduled to be available on the SITC website on November 9, 2020.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.

Dutch Translation/Nederlandse vertaling

Kiadis Pharma N.V. (‘Kiadis’) is een Nederlands beursgenoteerd biotechbedrijf dat nieuwe geneesmiddelen ontwikkelt tegen ernstige ziekten. Het maakt daarbij gebruik van Natural Killer-cellen (NK-cellen), grote witte bloedlichamen die de eerste verdedigingslinie in het menselijk afweersysteem vormen tegen kankercellen en infecties. Kiadis maakt bekend dat een zogeheten ‘poster’ is geaccepteerd voor presentatie op de jaarlijkse (thans virtuele) bijeenkomst van de Society for Immunotherapy of Cancer (SITC) van 9-14 november 2020.

De details van de posterpresentatie zijn:

• Poster # 454: Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures
  Presentator: Namita Varudkar
  Aangsloten bij: University of Central Florida
  Sessie categorie: Combinatie-immunotherapieën
  Presentatiedata: donderdag 12 november, 16.50-17.20 uur EST en zaterdag 14 november, 13:00 -13: 30 uur Est

Alle abstracts zijn naar verwachting beschikbaar op 9 november 2020 op de SITC-website.

De posters zijn beschikbaar vanaf maandag 9 november 8 uur EST in de ochtend tot de sluiting van de virtuele posterzaal op 31 december 2020.

Dit persbericht vormt een samenvatting van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.

Contacts

Kiadis: Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305 [email protected]

LifeSpring Life Sciences Communication: Leon Melens (Amsterdam) Tel: +31 538 16 427 [email protected] Optimum Strategic Communications: Mary Clark, Supriya Mathur Tel: +44 203 950 9144 [email protected] Kiadis_Twitter Kiadis_Twitter

About Kiadis

Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis' or, as appropriate, Kiadis' officers' current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.